EACS has selected a group of independent writers as the official providers of scientific news reporting for the 20th European AIDS Conference.
Gus Cairns, Roger Pebody, Keith Alcorn and Amelia Jones are reporting on key research presented at the Conference, publishing articles on the EACS website and those of partner organisations. Summary news bulletins will also be sent from the EACS mailing list. The writers are editorially independent of EACS and independent of study presenters.
EACS 2025 bulletin, October 2025
Europe is the only global region where HIV-related deaths increased between 2010 and 2022, the 20th European AIDS Conference (EACS 2025) heard in Paris. Teymur Noori of the European Centre for Disease Prevention and Control told delegates that Europe would miss most of the UNAIDS targets set for 2030, with war, funding cuts and political shifts deprioritising HIV as a global health issue.
The data paint a concerning picture. Whilst HIV-related deaths have halved globally since 2010, they have risen by a third in the WHO European region, which stretches from western Europe to central Asia. Deaths increased from 37,000 in 2010 to 51,000 in 2022 – more than five times the 2025 target. Many of these deaths are occurring in Russia and Ukraine. Even in wealthier EU and EEA countries, there were 2300 deaths in 2025, still more than twice the target.
Bulletin EACS 2025, octobre 2025
L’Europe est la seule région du monde où les décès liés au VIH ont augmenté entre 2010 et 2022, selon la 20e Conférence européenne sur le sida (EACS 2025) qui s’est tenue à Paris. Teymur Noori, du Centre européen de prévention et de contrôle des maladies, a déclaré aux délégués que l’Europe n’atteindrait pas la plupart des objectifs fixés par l’ONUSIDA pour 2030. La guerre, les coupes budgétaires et les changements politiques ont mis le VIH au second plan en tant qu’enjeux de santé mondiale.
Les données dressent un tableau préoccupant : alors que les décès liés au VIH ont diminué de moitié à l’échelle mondiale depuis 2010, ils ont augmenté d’un tiers dans la région européenne de l’OMS, qui s’étend de l’Europe de l’Ouest à l’Asie centrale. Le nombre de décès est passé de 37 000 en 2010 à 51 000 en 2022, soit plus de cinq fois la cible fixée pour 2025.
Une grande partie de ces décès surviennent en Russie et en Ukraine. Même dans les pays les plus riches del’UE et de l’EEE, 2 300 décès ont été recensés en 2025, soit plus du double de l’objectif fixé.
Boletín de la EACS 2025, octubre de 2025
Europa es la única región mundial donde las muertes relacionadas con el VIH se han incrementado entre 2010 y 2022, según se afirmó en la XX Conferencia Europea del Sida (EACS 2025), celebrada recientemente en París (Francia). Teymur Noori, del Centro Europeo para la Prevención y el Control de Enfermedades (ECDC, en sus siglas en inglés), afirmó en el encuentro que Europa no cumpliría la mayoría de los objetivos de ONUSIDA para 2030. La guerra, los recortes económicos y los cambios políticos han restado prioridad al VIH como asunto de salud mundial.
Los datos dibujan un panorama preocupante. Aunque las muertes relacionadas con el VIH en el mundo se han reducido a la mitad desde 2010, han aumentado un tercio en la región europea de la Organización Mundial de la Salud (OMS), que se extiende desde Europa occidental hasta Asia central. Así, el número de fallecimientos aumentó de 37.000 en 2010 a 51.000 en 2022, una cifra más de cinco veces superior al objetivo fijado para 2025. Gran parte de estas muertes se produjeron en Rusia y Ucrania. No obstante, incluso en los países más ricos de la Unión Europea (UE) y el Espacio Económico Europeo (EEE), se registraron 2.300 fallecimientos relacionados con el VIH en 2025, lo que sigue constituyendo más del doble del objetivo fijado.
Boletim EACS 2025, outubro de 2025
A Europa é a única região do mundo onde as mortes relacionadas com o VIH aumentaram entre 2010 e 2022, de acordo com o anunciado na 20.ª Conferência Europeia sobre a SIDA (EACS 2025), realizada em Paris. Teymur Noori, do Centro Europeu de Prevenção e Controlo de Doenças, afirmou que a Europa não iria cumprir a maioria das metas da ONUSIDA estabelecidas para 2030, com a guerra, os cortes no financiamento e as mudanças políticas a retirar a prioridade ao VIH como questão de saúde global.
Os dados apresentam um quadro preocupante. Embora as mortes relacionadas com o VIH tenham diminuído pela metade globalmente desde 2010, estas aumentaram um terço na região europeia da OMS, que se estende da Europa Ocidental à Ásia Central. As mortes aumentaram de 37 000 em 2010 para 51 000 em 2022 – mais de cinco vezes a meta para 2025. Muitas dessas mortes estão a ocorrer na Rússia e na Ucrânia. Mesmo nos países mais ricos da UE e do EEE, houve 2300 mortes em 2025, superior ao dobro da meta.
Bollettino EACS 2025, ottobre 2025
L’Europa è l’unica regione globale ad aver registrato un aumento dei decessi HIV-correlati tra il 2010 e il 2022, si è appreso alla 20° Conferenza Europea sull’AIDS (EACS 2025) di Parigi. Teymur Noori del Centro Europeo per la Prevenzione e il Controllo delle Malattie (ECDC) ha riferito che l’Europa rischia di non raggiungere la maggior parte degli obiettivi fissati da UNAIDS per il 2030, ora che il problema di salute globale rappresentato dall’HIV sta perdendo posizioni nella lista delle priorità a causa di guerre, dei tagli ad aiuti e finanziamenti e dei mutamenti politici in corso.
I dati dipingono uno scenario preoccupante. Mentre i decessi HIV-correlati dal 2010 si sono dimezzati a livello globale, nella regione europea dell’OMS (che si estende dall’Europa occidentale all’Asia centrale) sono aumentati di un terzo, passando dai 37.000 del 2010 a 51.000 nel 2022: una cifra che supera di ben cinque volte l’obiettivo fissato per il 2025. Molti sono decessi registrati in Russia e Ucraina, ma anche nei paesi più ricchi dell’Unione Europea e dello Spazio Economico Europeo (SEE) se ne sono conteggiati 2300, ossia ancora più del doppio rispetto all’obiettivo.
Бюлетень EACS 2025, жовтень 2025 р.
[зображення] Презентація Теймура Нурі на EACS 2025. Фото: @eacsociety.bsky.social
Європа є єдиним світовим регіоном, де смертність, пов’язана з ВІЛ, зросла в період з 2010 по 2022 рік, — це було заявлено на 20-й Європейській конференції зі СНІДу (EACS 2025) у Парижі. Теймур Нурі з Європейського центру профілактики та контролю захворювань повідомив делегатам, що Європа не буде здатна досягнути більшості цілей UNAIDS, встановлених на 2030 рік, — внаслідок війни, скорочення фінансування та політичних зрушень, що знижують пріоритетність ВІЛ як глобальної проблеми охорони здоров’я.
Бюллетень Европейского Клинического СПИД Сообщества (EACS 2025), октябрь 2025 г.
Европа в глобальном масштабе является единственным регионом, в котором смертность по причине ВИЧ-инфекции возросла между 2010 и 2022 годами – прозвучало на ХХ-ой Европейской СПИД-конференции (EACS 2025) в Париже. Тимур Нури из Европейского Центра надзора и профилактики заболеваний сказал, что Европа отстает в достижении большинства целей, намеченных ЮНЭЙДС на 2030 год, по причине войны, сокращения уровня финансирования и политических сдвигов, деприоритизирующих ВИЧ-инфекцию, как глобальной проблемы здравоохранения.
Статистические данные отражают настораживающую картину. В то время как уровень ВИЧ-смертности во всем мире с 2010 года сократился вдвое, в Европейском регионе ВОЗ, простирающегося с Западной Европы до Центральной Азии, этот показатель повысился на треть. Уровень смертности увеличился с 37 000 случаев в 2010 году до 51 000 случаев в 2022 году, что превышает целевой показатель 2025 года более, чем в пять раз. Большинство этих случаев регистрируются в России и Украине. Даже в странах ЕС и ЕЭЗ с более благоприятной финансовой обстановкой было зарегистрировано 2300 случаев смертей, что превышает целевой показатель более, чем в два раза.
A Dutch study presented at the 20th European AIDS Conference (EACS 2025) in Paris compared the health-related quality of life (HRQoL) in around 500 older people with HIV with the same number of carefully matched people without HIV for the last decade.
It found that although the people with HIV reported consistently lower quality of life as measured by a 36-point questionnaire, the difference was very slight and unlikely to be of clinical significance. There was also no decline seen in HRQoL in participants, regardless of HIV status, between their first assessment and their last, eight years later. (On average, they aged from 52-53 to 60-61 during that time.)
However, study participants also completed a questionnaire that asked about symptoms of depression. This found significantly more experience of depression among the HIV-positive participants than the HIV-negative ones, to the extent that the positive ones significantly exceeded the threshold score that would suggest clinical depression (16 points out of a maximum of 60). The HIV-negative participants did not.
Europe, taken as a whole, is losing some of the gains it has made in tackling the burden of HIV, the 20thEuropean AIDS Conference (EACS 2025) heard in Paris.
Teymur Noori of the European Centre for Disease Prevention and Control (ECDC) told delegates that Europe would miss out on achieving most of the targets UNAIDS had set for the year 2030.
UNAIDS first proposed the targets in 2014, although they were revised in 2021 to include interim targets for 2025, in recognition of the impact of the COVID pandemic. Since then, however, war in many places including Palestine and Ukraine, deep cuts to global HIV budgets from the US and European countries, and a general rightward shift in world politics have all served to deprioritise HIV as a global health issue. So falling short of those ambitious targets is no great surprise.
Although virological failure of injectable cabotegravir/rilpivirine is rare, viral rebound can lead to resistance mutations that may exclude future treatment with widely used antiretrovirals, studies presented last week at the 20th European AIDS Conference (EACS 2025) in Paris show.
While the integrase inhibitor cabotegravir has a high barrier to the development of resistance mutations, resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine can emerge quickly after viral rebound. This is especially true if the virus already carries naturally occurring mutations that increase susceptibility to rilpivirine resistance.
Long-acting injectable treatment can overcome the adherence difficulties that often lead to treatment failure, but injectable cabotegravir/rilpivirine (CAB/RPV) treatment may fail due to other factors such as low drug concentrations. If treatment fails, the resistance profile is uncertain.
Two large studies of people switching to tenofovir-sparing regimens presented at the 20th European AIDS Conference (EACS 2025) in Paris show that hepatitis B reactivation is a rare event after the hepatitis B-suppressive drug is removed.
Hepatitis B virus (HBV) can be successfully suppressed by antiretroviral regimens containing tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF). Switching to a tenofovir-sparing, two-drug HIV treatment regimen poses a risk of hepatitis B reactivation in people with past hepatitis B exposure. As such regimens – including dolutegravir/lamivudine and cabotegravir/rilpivirine – are more widely used, there have been concerns that hepatitis B reactivation may be seen more frequently in people with HIV.
At the 20th European AIDS Conference (EACS 2025) in Paris last week, delegates received an update on a case of an apparent cure of HIV infection that was first presented at the 2024 International AIDS Conference in Munich.
The ‘second Berlin patient’ received a stem cell transplant in late 2015 that cured the acute myeloid leukaemia he was suffering from. It also appears to have cured his HIV infection, as he has now been off antiretroviral therapy (ART) for seven years without his HIV reappearing. Researchers have found no DNA in his cells capable of giving rise to new virus, and his antibody response to HIV is fading, indicating there’s no virus for the immune system to respond to.
Ukraine’s health services have been remarkably resilient in wartime, with technological innovations playing a key role in sustaining the delivery of care. At the 20th European AIDS Conference (EACS 2025) in Paris last week, Tetiana Deshko of the Alliance for Public Health outlined three key uses of artificial intelligence (AI) – ‘digital humans’ to answer queries and enhance access to health care; machine learning to better target the offer of HIV testing; and AI-guided analysis to help the organisation strengthen its resilience planning.
The European AIDS Clinical Society issued updated guidelines at its 20th European AIDS Conference (EACS 2025) in Paris last week, making new recommendations on infant feeding and diagnosis and management of obesity in people with HIV.
Antiretrovirals for treatment and prevention
The updated guidelines make no new recommendations on starting or changing treatment, except in relation to people who acquire HIV when using PrEP. In this case, the updated guidelines recommend that dual antiretroviral therapy (ART) regimens should be avoided. For people who acquire HIV when taking long-acting cabotegravir, treatment should start with boosted darunavir and two active nucleoside reverse transcriptase inhibitors.
Studies presented last week at the 20th European AIDS Conference (EACS 2025) in Paris highlighted the need for tailored cancer screening strategies in people with HIV.
The studies found that prostate cancer presents earlier and is more advanced in men with HIV and that women with a lower nadir CD4 count have greater risk of both anal and cervical cancer. A study of liver cancer screening showed that people with HIV without cirrhosis often fail to receive screening despite risk factors, while women with HIV often do not perceive themselves to be at risk of anal cancer despite a high prevalence of HPV associated with cancer among those screened.
Progress towards wider use of statins in people with HIV has been modest and LDL cholesterol control remains suboptimal in people with HIV at higher risk of cardiovascular disease, studies presented at last week’s 20th European AIDS Conference (EACS 2025) in Paris show.
In 2011, the European Society of Cardiology (ESC) recommended statins for people living with HIV with elevated cholesterol. Earlier this year, the ESC recommended statins for all people with HIV aged 40 and over, regardless of cardiovascular risk and LDL cholesterol levels, following the results of the REPRIEVE study. This international randomised study showed that statin treatment reduced the risk of major cardiovascular events by 36% in people with HIV with low-to-intermediate cardiovascular risk.
Switching to a two-drug regimen of dolutegravir/lamivudine (Dovato) resulted in significantly less weight gain after 96 weeks compared to a switch to tenofovir alafenamide/emtricitabine/bictegravir (Biktarvy), the final results of a large, randomised trial conducted in Spain have shown.
Dr Esteban Martinez of the Hospital Clinic Barcelona presented 96-week results of the PASO-DOBLE study last week at the 20th European AIDS Conference (EACS 2025) in Paris.
Some studies have ruled out any contribution of antiretroviral drug type to weight gain after starting or switching treatment. However, Professor Dominique Costagliola argued in a session on weight gain that studies consistently show a greater effect on weight associated with treatment containing tenofovir alafenamide (TAF), bictegravir or dolutegravir.
A significant number of presentations at last week’s 20th European AIDS Conference (EACS 2025) in Paris were concerned with the bacterial sexually transmitted infections (STIs) syphilis, gonorrhoea and chlamydia rather than HIV. This is largely because using the antibiotic doxycycline to forestall infection after possible exposures – doxyPEP – has become more common in western Europe.
This is despite doxyPEP being subject to differing opinions among experts. Whereas the UK’s STI professional society BASHH issued guidelines for doxyPEP use on 9th June this year, a year after the US CDC issued its own, the European equivalent, ECDC, has yet to release its guidelines, though a draft document is currently out for consultation. Reservations concerning doxyPEP centre on its limited efficacy against gonorrhoea and whether it will lead to an increase in antimicrobial drug resistance.
A study presented at the recent 20th European AIDS Conference (EACS 2025) has found that the apparent rise in sexually transmitted infections (STIs), at least in gay and bisexual men with HIV in France, are due to more frequent testing rather than more infections.
Dr Sophie Novelli of the Centre for Epidemiology and Population Health (CESP) of the French national scientific health research agency INSERM presented data from 2016 to 2023 taken from the PRIMO cohort.
The way gay and bisexual men are using drugs to enhance sex (chemsex) is changing in Europe, especially among younger men and those new to chemsex. They are turning to a new generation of drugs, generally with shorter half-lives. These include synthetic cathinones similar to mephedrone, but there are signs that hallucinogens like LSD are also regaining popularity.
People with newer patterns of drug use and new arrivals to the chemsex scene in general may be especially at risk of HIV and sexually transmitted infections (STIs), because their adherence to PrEP seems lower than among other groups, Professor Kai Jonas of the University of Maastricht told the recent 20th European AIDS Conference (EACS 2025) in Paris.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from Turnstile to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Vimeo. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from YouTube. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More InformationYou are currently viewing a placeholder content from Facebook. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More Information